Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62
The immunogenicity of specific varicella-zoster virus (VZV) proteins, with emphasis upon cell-mediated immune responses, was evaluated by immunizing strain 2 guinea-pigs with vaccinia virus recombinants that express gpI (vac-gpI), gpIV (vac-gpIV) and gpV (vac-gpV) or the IE-62 protein (vac-IE-62). Vac-gpI elicited the highest initial mean T cell proliferation response [stimulation index (S.I.) 3.8 ± 0.9 s.e.m.] whereas inoculation with vac-gpV produced the lowest primary T cell response (S.I. 2.5 ± 1.1 s.e.m.). T cell proliferation was detected for a shorter period after immunization with vac-gpV compared to vac-gpI, vac-gpIV or vac-IE-62. A comparison of the immunogenicity of vac-gpI and vac-IE-62 with the same proteins prepared by immunoaffinity purification showed that immunization with these proteins in either form elicited virus-specific IgG antibodies and T cell recognition. The presence or absence of IgG antibodies to the IE-62 protein was used to assess protection against challenge with guinea-pig cell-adapted infectious VZV in animals that had been inoculated with vac-gpI, vac-gpIV or vac-gpV. Immunization with vac-gpI and vac-gpIV restricted VZV replication but all animals given vac-gpV developed antibodies to IE-62 after challenge with infectious VZV. Priming of the T lymphocyte response was observed in all animals immunized with VZV-vaccinia virus recombinants after subsequent exposure to infectious VZV. These experiments with VZV vac-gpI, vac-gpIV and vac-gpV in guinea-pigs suggest variability in the capacity of herpesviral glycoproteins to elicit cell-mediated immunity in vivo. Induction of virus-specific immunity using IE-62 means that this major tegument protein of VZV could be a useful component for vaccine development.
ArvinA. M.,
KoropchakC. M.,
WittekA. E.1983; Immunologic evidence of reinfection with varicella-zoster virus. Journal of Infectious Diseases 148:200–205
ArvinA. M.,
KoropchakC. M.,
WilliamsB. R. G.,
GrumetF. C.,
FoungS. K.1986a; Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. Journal of Infectious Diseases 154:422–429
ArvinA. M.,
Kinney-ThomasE.,
ShriverK.,
GroseC.,
KoropchakC. M.,
ScrantonE.,
WittekA. E.,
DiazP. S.1986b; Immunity to varicella-zoster viral glycoproteins, gpI (90/58) and gpIII (gp 118) and to a nonglycosylated protein, p170. Journal of Immunology 137:1346–1351
ArvinA. M.,
SolemS. M.,
KoropchakC. M.,
Kinney-ThomasE.,
ParyaniS. G.1987; Humoral and cellular immunity to varicella-zoster virus glycoprotein, gpI, and to a non-glycosylated protein, p170, in the strain 2 guinea-pig. Journal of General Virology 68:2449–2454
ArvinA. M.,
SharpM.,
SmithS.,
KoropchakC. M.,
DiazP. S.,
KinchingtonP.,
RuyechanW.,
HayJ.1991; Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T-lymphocytes of either CD4+ or CD8+ phenotype. Journal of Immunology 146:257–264
BermanP. W.,
GregoryT.,
CraseD.,
LaskyL. A.1985; Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science 227:1490–1492
BernsteinD. I.,
StanberryL. R.,
KappesJ. C.,
BurkeR. L.,
MeyersM. G.1988; Antibody to herpes simplex virus (HSV) ICP-35 proteins after HSV challenge of animals immunized with HSV subunit vaccines. Journal of Infectious Diseases 157:1178–1186
BullerR. M. L.,
SmithG. L.,
CremerK.,
NotkinsA. L.,
MossB.1985; Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature, London 317:813–815
ChildS. J.,
PalumboG.,
BullerM.,
HrubyD. E.1990; Insertional inactivation of the vaccinia virus M1 subunit of ribonucleotide reductase results in in vivo attenuation of recombinant virions. Virology 174:625–629
DavisonA. J.,
WatersD. J.,
EdsonC. M.1985; Identification of the products of a varicella-zoster virus glycoprotein gene. Journal of General Virology 66:2237–2242
DiazP. S.,
SmithS.,
HunterE.,
ArvinA. M.1988; Immunity to varicella-zoster virus antigen, glycoprotein I (gpI) and a nonglycosylated protein (p170): relation to the immunizing regimen of live attenuated varicella vaccine. Journal of Infectious Diseases 158:1245–1252
FelsenfeldA. D.,
SchmidtN. J.1979; Varicella-zoster virus immunizes patas monkeys against simian varicella-like disease. Journal of General Virology 42:171–178
FriedrichsW. E.,
GroseC.1984; Glycoprotein gp118 of varicella-zoster virus: purification by serial affinity chromatography. Journal of Virology 49:992–996
GönczölE.,
HudeczF.,
IanaconeJ.,
DietzscholdB.,
StarrS.,
PlotkinS. A.1986; Immune responses to the isolated human cytomegalovirus envelope proteins. Journal of Virology 58:661–664
HaywardA. R.,
BurgerR.,
ScheperR.,
ArvinA. M.1991; Major histocompatibility complex restriction of T cell responses to varicella-zoster virus in guinea pigs. Journal of Virology 65:1491–1495
KellerP. M.,
NeffB. J.,
EllisR. W.1984; Three major glycoprotein genes of varicella-zoster virus whose products have neutralization epitopes. Journal of Virology 52:293–297
KinchingtonP. R.,
RemenickJ.,
OstroveJ. M.,
StrausS. E.,
RuyechanW. T.,
HayJ.1986; Putative glycoprotein gene of varicella-zoster virus with variable copy numbers of a 42-base pair repeat sequence has homology to herpes simplex virus glycoprotein C. Journal of Virology 59:660–668
KinchingtonP. R.,
LingP.,
PensieroM.,
MossB.,
RuyechanW. T.,
HayJ.1990; The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). Journal of Virology 64:4540–4548
KinchingtonP. R.,
HouglandJ. K.,
ArvinA. M.,
RuyechanW. T.,
HayJ.1991; Varicella zoster virus IE 62 protein is a major virion component. Journal of Virology (in press)
KoropchakC. M.,
SolemS. M.,
DiazP. S.,
ArvinA. M.1989; Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. Journal of Virology 63:2392–2395
MatsunagaY.,
YamanishiK.,
TakahashiM.1982; Experimental infection and immune response of guinea pigs with varicellazoster virus. Infection and Immunity 37:407–412
MeignierB.,
JourdierT. M.,
NorrildB.,
PereiraL.,
RoizmanB.1987; Immunization of experimental animals with reconstituted mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus. Journal of Infectious Diseases 155:921–930
RobertsP. L.,
DuncanB. E.,
RaybouldT. J. G.,
WatsonD. H.1985; Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge. Journal of General Virology 66:1073–1083
SekulovichR. E.,
NgP.,
BurkeR. L.1990; Immunization of guinea pigs with a vaccinia/VP16 recombinant virus elicits neutralizing antibody titers and protects against HSV-2 challenge. Abstracts, 15th International Herpesvirus Workshop p. 395
VafaiA.,
WroblewskaZ.,
MahalingamR.,
CabiracG.,
WellishM.,
CiscoM.,
GildenD.1988; Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies. Journal of Virology 62:2544–2551
WachsmanM.,
AurelianL.,
SmithC. C.,
LipinskasB. R.,
PerkusM. E.,
PaolettiE.1987; Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. Journal of Infectious Diseases 155:1188–1197
WeirJ. P.,
BennettM.,
AllenE. M.,
ElkinsK. L.,
MartinS.,
RouseB. T.1989; Recombinant vaccinia virus expressing the herpes simplex type 1 glycoprotein C protects mice against herpes simplex virus challenge. Journal of General Virology 70:2587–2594
WilleyD. E.,
CantinE. M.,
HillL. R.,
MossB.,
NotkinsA. L.,
OpenshawH.1988; Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection. Journal of Infectious Diseases 158:1382–1385
YaoF.,
CourtneyR. J.1989; A major transcriptional regulatory protein (ICP4) of HSV-1 is associated with purified virions. Journal of Virology633338–3344
Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62